Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018

References

• Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307. doi:10.1016/j.meegid.2016.08.03127587334
   PubMed Web of Science ®Google Scholar
• Rossouw TM, Nieuwoudt M, Manasa J, et al. HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa. HIV Med. 2017;18(2):104–114. doi:10.1111/hiv.1240027353262
   PubMed Web of Science ®Google Scholar
• World Health Organization: HIV drug resistance report; 2019 Available from: https://www.who.int/hiv/pub/drugresistance/hivdr-report-2019/en/. Accessed 717, 2019.
   Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005;4(3):236–248. doi:10.1038/nrd166015729361
   PubMed Web of Science ®Google Scholar
• Chen Q, Cheng X, Wei D, et al. Molecular dynamics simulation studies of the wild type and E92Q/N155H mutant of elvitegravir-resistance HIV-1 integrase. Interdiscip Sci. 2015;7(1):36–42. doi:10.1007/s12539-014-0235-825519157
   PubMed Web of Science ®Google Scholar
• AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association; Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV/AIDS (Version 2018). Zhonghua Nei Ke Za Zhi. 2018;57(12):867–884. doi:10.3760/cma.j.issn.0578-1426.2018.12.002.30486555
   PubMedGoogle Scholar
• DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials. 2012;13(4):228–232. doi:10.1310/hct1304-22822849964
   PubMed Web of Science ®Google Scholar
• Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927–935. doi:10.1016/S1473-3099(13)70257-324074642
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, Phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072. doi:10.1016/S0140-6736(17)32299-728867497
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013;13(7):587–596. doi:10.1016/S1473-3099(13)70093-823664333
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807–816. doi:10.1093/cid/cir51021921224
   PubMed Web of Science ®Google Scholar
• Choi E, Mallareddy JR, Lu D, et al. Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase. Future Sci OA. 2018;4(9):FSO338. doi:10.4155/fsoa-2018-006030416746
   PubMed Web of Science ®Google Scholar
• Casadellà M, van Ham PM, Noguera-Julian M, et al. Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother. 2015;70(10):2885–2888. doi:10.1093/jac/dkv20226188038
   PubMed Web of Science ®Google Scholar
• Rangel HR, Garzaro D, Fabbro R, et al. Absence of primary integrase resistance mutations in HIV type 1-infected patients in Venezuela. AIDS Res Hum Retroviruses. 2010;26(8):923–926. doi:10.1089/aid.2010.003920704494
   PubMed Web of Science ®Google Scholar
• Ji H, Patterson A, Taylor T, et al. Prevalence of primary drug resistance against HIV-1 integrase inhibitors in Canada. J Acquir Immune Defic Syndr. 2018;78(1):e1–e3. doi:10.1097/QAI.000000000000164929424788
   PubMed Web of Science ®Google Scholar
• Inzaule SC, Hamers RL, Noguera-Julian M, et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J Antimicrob Chemother. 2018;73(5):1167–1172. doi:10.1093/jac/dky00529462322
   PubMed Web of Science ®Google Scholar
• Stekler JD, McKernan J, Milne R, et al. Lack of resistance to integrase inhibitors among antiretroviral-naïve subjects with primary HIV-1 infection, 2007–2013. Antivir Ther. 2014;20(1):77–80. doi:10.3851/IMP278024831260
   PubMed Web of Science ®Google Scholar
• Liu L, Dai L, Yao J, et al. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naïve individuals in a tertiary care hospital in Beijing, China. AIDS. 2019;33(12):1945–1947. doi:10.1097/QAD.000000000000228231491787
   PubMed Web of Science ®Google Scholar
• Deng XM, Liu JF, Zhang M, et al. Mutations of primary integrase gene resistance of HIV/AIDS patients in Yunnan province. Clin J AIDS STD. 2019;25(4):327–341. doi:10.13419/j.cnki.aids.2019.04.01
   Google Scholar
• Van Laethem K, Schrooten Y, Covens K, et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods. 2008;153(2):176–181. doi:10.1016/j.jviromet.2008.07.00818706932
   PubMed Web of Science ®Google Scholar
• Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis. 2011;203(9):1204–1214. doi:10.1093/infdis/jir02521459813
   PubMed Web of Science ®Google Scholar
• Boyd SD, Maldarelli F, Sereti I, et al. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther. 2011;16(2):257–261. doi:10.3851/IMP174921447876
   PubMed Web of Science ®Google Scholar
• Rhee SY, Gonzales MJ, Kantor R, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31(1):298–303. doi:10.1093/nar/gkg10012520007
   PubMed Web of Science ®Google Scholar
• Bradley-Stewart A, Urcia C, MacLean A, Aitken C, Gunson R. HIV-1 integrase inhibitor resistance among treatment naïve patients in the West of Scotland. J Clin Virol. 2017;92:7–10. doi:10.1016/j.jcv.2017.04.01228494325
   PubMed Web of Science ®Google Scholar
• Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001;58(1):19–42. doi:10.1093/bmb/58.1.1911714622
   PubMed Web of Science ®Google Scholar
• Neher RA, Leitner T, Fraser C. Recombination rate and selection strength in HIV intra-patient evolution. PLoS Comput Biol. 2010;6(1):e1000660. doi:10.1371/journal.pcbi.1000660.20126527
   PubMed Web of Science ®Google Scholar
• Han YS, Mesplède T, Wainberg MA. Differences among HIV-1 subtypes in drug resistance against integrase inhibitors. Infect Genet Evol. 2016;46:286–291. doi:10.1016/j.meegid.2016.06.04727353185
   PubMed Web of Science ®Google Scholar
• Depatureaux A, Mesplède T, Quashie P, et al. HIV-1 Group O resistance against integrase inhibitors. J Acquir Immune Defic Syndr. 2015;70(1):9–15. doi:10.1097/QAI.000000000000069826017662
   PubMed Web of Science ®Google Scholar
• Van Laethem K, Theys K, Vandamme AM. HIV-1 genotypic drug resistance testing: digging deep, reaching wide? Curr Opin Virol. 2015;14:16–23. doi:10.1016/j.coviro.2015.06.00126114581
   PubMed Web of Science ®Google Scholar
• Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002;18(4):243–248. doi:10.1089/08892220275347280111860670
   PubMed Web of Science ®Google Scholar